Share this article
Share this article
MONTRÉAL, April 19, 2021 /CNW Telbec/ - On the occasion of its Annual General Meeting, Aéro Montréal will share today the many achievements of the Québec aerospace cluster in 2020. It will also take the opportunity to unveil the proposed measures developed by the Alliance for the Aerospace Recovery, a strategic committee created under the direction of its Board of Directors.
Measures adapted to the needs of the industry
In response to the biggest crisis ever to hit the aerospace industry, Aéro Montréal proposed a collective and mobilizing approach by bringing together top executives from each segment of the supply chain, the various levels of government and the financial community to create the Alliance for the Aerospace Recovery (AAR).
Ionis initiates pivotal clinical study of novel antisense medicine to treat patients with Alexander disease
- Innovative therapy targeting the root cause of the disease has received orphan drug designation by the U.S. FDA and European Medicines Agency
- ION373 is one of Ionis wholly owned rare disease medicines the company plans to commercialize
News provided by
Share this article
Share this article
CARLSBAD, Calif., April 20, 2021 /PRNewswire/ Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced it has initiated a pivotal clinical study of ION373 in patients with Alexander disease, a rare and generally fatal neurological disorder. Alexander disease patients experience progressive deterioration, leading to severe disability and loss of independence. Childhood onset is associated with more serious disease, with patients rarely surviving beyond adolescence. Alexander disease is caused by a genetic mutation that leads to overproduction and toxic accumulation of glial fi
Share this article
GOTHENBURG, Sweden, April 20, 2021 /PRNewswire/
Vicore Pharma Holding AB (publ) ( Vicore ), a pharmaceutical company developing innovative medicines for severe lung disorders such as idiopathic pulmonary fibrosis (IPF), today announced that it will host a key opinion leader (KOL) webinar on C21, the company s lead asset for the treatment of COVID-19, on Wednesday, April 28, 2021 at 14:00 CET (8 am EST).
The event will feature a presentation by KOL Professor Maureen Horton, M.D., Johns Hopkins University School of Medicine, who will discuss the current treatment landscape and unmet medical needs in treating patients with COVID-19. Professor Horton will be available to answer questions following the conclusion of the event.
Point of Care Test Market is Ravaged, and Helped By Pandemic
News provided by
Share this article
Share this article
ARLINGTON, Va., April 20, 2021 /PRNewswire/ Kalorama Information reported a mixed result with point of care testing, defined by tests that can deliver a result meaningful during a patient visit with a provider or on their own. In 2020, sales of POC testing reached $29,316 million, according to Kalorama Information, a sister publication to Lab Pulse. That s up double digits from 2019, which would normally be pretty intense growth according to the Arlington, VA-based producer of IVD market research reports, but the growth in sales belies the reduction of business for the average point-of-care test product. New COVID-19 tests fueled growth while the pandemic ravaged business in other test categories. This according to Kalorama s Information Worldwide Market for Point of Care.
Share this article
Share this article
SOUTH SAN FRANCISCO, Calif., April 20, 2021 /PRNewswire/ Vera Therapeutics, Inc., a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Celia Lin, MD, as Chief Medical Officer. Dr. Lin brings extensive clinical and industry experience in orphan diseases and multiple therapeutic areas, including nephrology and inflammation. In addition, the Company announced the appointments of Tad Thomas, PhD, as Senior Vice President (SVP) and Head of Product Development and Manufacturing and Joseph Young, MBA, as SVP of Finance.
Vera Therapeutics Appoints Industry Veteran Dr. Celia Lin as Chief Medical Officer